Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program

Top-Line Results Expected in First Half of 2017

Novan, Inc. today announced that the first patient has been dosed in the Company’s Phase 2 clinical program to evaluate the efficacy and safety of topical nitric oxide product candidate SB208 in the treatment of infections caused by dermatophytes such as¬†Trichophyton rubrum¬†(“T. rubrum”). Novan is developing SB208 as a broad-spectrum anti-fungal gel for the treatment of infections of the skin and nails, including athlete’s foot and onychomycosis.